FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
171st Meeting of the Vaccines and Related Biological Products Advisory Committee
April 6, 2022
DRAFT AGENDA

Topic: The committee will meet in open session to discuss considerations for COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants

Time	Presentation/Presenter
8:30 a.m.	**Opening Remarks: Call to Order and Welcome (10 min)** Arnold Monto, M.D. Acting Chair, VRBPAC Emeritus Professor of Public Health and Epidemiology, University of Michigan **Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 min)** Prabhakara Atreya, Ph.D. Acting Designated Federal Officer, VRBPAC Director, Division Scientific Advisors and Consultants, CBER, FDA
9:00 a.m.	**FDA Introduction (15 min)** **Welcome (5 min)** • Peter Marks, M.D. Ph.D. Center Director, CBER, FDA **Introduction to the Topic: COVID-19 vaccine booster vaccination (10 min)** • Doran Fink, M.D., Ph.D. Deputy Director- Clinical Division of Vaccines and Related Product Applications (DVRPA) Office of Vaccines Research and Review (OVRR), CBER, FDA
9:15 a.m.	**Update on the Epidemiology of COVID-19 Variants (35 min)** • CDR Heather Scobie, PhD, M.PH. (30 min) Deputy Team Lead, Surveillance and Analytics Epidemiology Task Force COVID-19 Emergency Response Centers for Disease Control and Prevention (CDC) • Q/A – 5 min
9:50 a.m.	**COVID-19 Vaccine Effectiveness in Children and Adults (25 min)** • LCDR Ruth Link-Gelles, PhD, M.PH. (20 min) Program Lead, COVID-19 Vaccine Effectiveness Epidemiology Task Force COVID-19 Emergency Response

	Centers for Disease Control and Prevention (CDC) • Q/A – 5 min
10:20 a.m.	**Israeli Experience with Fourth Booster Doses in Older Adults (20 min)** • Sharon Alroy-Preis, M.D. M.PH.M.B.A – (10 min) Director, Public Health Services Ministry of Health, Jerusalem, Israel • Ron Milo. Ph.D. - (5 Min) Professor, Dept. of Plant and Environmental Sciences, Dean of Education, Weissman Institute, Rehovot, Israel Q/A – 5 min
10:40 a.m.	**Break (10 min)**
10:50 a.m.	**Predicting Future SARS-CoV-2 Variants (30 min)** • John Beigel, M.D. (10 min) Associate Director for Clinical Research Division of Microbiology and Infectious Diseases Office of the Director, NIAID, NIH • Trevor Bedford, Ph.D. (10 Min) Professor, Fred Hutchinson Cancer Research Center Investigator, Howard Hughes Medical Inst. Seattle, WA • Q &A – 10 Min
11:20 a.m.	**Modeling of Future U.S. COVID-19 Outbreaks (30 min)** • Christopher Murray, M.D. D.Phil. (15 Min) Professor and Chair Department of Health Metrics Sciences Director, Institute for Health Metrics and Evaluation (IHME) • Ali H. Mokdad, Ph.D. (5 min) Professor, Health Metrics Sciences Chief Strategy Officer, Population Health Institute for Health Metrics and Evaluation (IHME) School of Medicine, Washington University • Q &A – 10 Min

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
171st Meeting of the Vaccines and Related Biological Products Advisory Committee
April 6, 2022
DRAFT AGENDA

11:50 a.m.	**WHO Perspective on Variants for COVID-19 Vaccine Composition (20 min)** • Kanta Subbarao, M.D. M.PH. (15 min) Director, WHO Collaborating Center for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity Melbourne, Australia • Q &A – 5 min
12:10 p.m.	**Perspective on Variant Vaccine Development and Production (20 min)** • Robert Johnson, Ph.D. (15 min) Deputy Assistant Secretary Director, Medical Countermeasure Programs Biomedical Advanced Research and Development Authority (BARDA) • Q &A – 5 min
12:30 p.m.	**Proposed Framework for Addressing Future COVID-19 Outbreaks (30 min)** • Jerry Weir, Ph.D. (20 min) Director, Division of Viral Products Office of Vaccines Research and Review (OVRR), CBER, FDA • Q/A – 10 min
1:00 p.m.	**Lunch (30 min)**
1:30 p.m.	**Open Public Hearing (60 min)**
2:30 p.m.	**Committee Discussion of Questions (150 min)**
5:00 p.m.	**Meeting Adjourned**